Freeze-Dried Plasma for Emergency Use in Dogs
The U.S. Food and Drug Administration (FDA) has completed a risk review of Mantel’s Canine Freeze-Dried Plasma (cFDP), a pooled allogeneic canine plasma product intended for the treatment of hypovolemia and control of hemorrhage in dogs.
Based on its evaluation, FDA concluded that the product’s potential risks have been appropriately identified and mitigated and that the agency does not intend to object to marketing of the product at this time, despite the product not being formally approved, conditionally approved, or index listed.
This determination is notable for veterinary professionals, manufacturers, and regulatory stakeholders, as it reflects FDA’s risk-based approach to animal health products designed for acute, emergency use scenarios.
Scope of FDA’s Review
FDA’s Center for Veterinary Medicine evaluated Mantel’s cFDP across multiple dimensions, including product characteristics and formulation, manufacturing processes and controls, donor eligibility criteria, available scientific literature on freeze-dried plasma, clinical and field studies conducted using Mantel’s cFDP, and a comparative assessment against other plasma products, such as fresh frozen plasma
Based on the totality of evidence, FDA concluded that Mantel Technologies has appropriately mitigated risks associated with the product and that cFDP demonstrates properties comparable to other canine plasma products, with no additional safety concerns identified at this time.
Regulatory Status: What This Does – and Does Not – Mean
It is important to distinguish FDA’s conclusion from formal product approval pathways.
Mantel’s cFDP is not approved, conditionally approved, or index listed.
FDA’s determination reflects regulatory enforcement discretion, not market authorization.
And FDA has stated it does not intend to object to marketing of the product based on the current risk profile.
This approach underscores FDA’s increasing reliance on risk-based regulatory decision-making, particularly where products address unmet medical needs in emergency or austere settings.
Practical Implications for Veterinary Medicine
Mantel’s cFDP offers several operational advantages over traditional blood and plasma products: Shelf stability of at least one year; no requirement for refrigeration or freezing; rapid reconstitution for intravenous use, and utility in trauma cases, military working dogs, and remote or field environments.
By contrast, fresh blood and plasma products often require cold storage, have limited shelf life, and may need thawing prior to administration – constraints that can delay treatment in critical situations.
Prescription Use and Professional Oversight
FDA emphasized that Mantel’s cFDP is available by prescription only, intended for use under the supervision of a licensed veterinarian, and dependent on specialized veterinary medical expertise for safe administration.
Each single-use kit contains 20 grams of freeze-dried plasma in a 250 mL bag, 250 mL sterile water for injection, and an administration set for intravenous delivery
Why This Matters from a Regulatory Perspective
This FDA action highlights several broader trends in veterinary regulation:
- Risk-based flexibility for products addressing urgent or unmet needs
- Growing attention to manufacturing controls, donor qualification, and comparability rather than pathway labels alone, and
- Increased regulatory openness to innovative formats (e.g., freeze-dried biologics) when safety risks are demonstrably managed.
For animal medical product developers, this case illustrates how robust risk identification, mitigation strategies, and scientific justification can influence FDA’s regulatory posture – even outside traditional approval frameworks.
About the Product Developer
Mantel’s Canine Freeze-Dried Plasma was developed by Mantel Technologies, based in Fort Collins, Colorado.